Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

908
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
908
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

924
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
924
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

941
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
941
ECG Interpretation of Arrhythmias I: Sinus Arrhythmias01:16

ECG Interpretation of Arrhythmias I: Sinus Arrhythmias

203
Arrhythmias are disturbances in the heart's rhythm that lead to abnormal heartbeats. These irregularities can originate from different parts of the heart and are classified based on their origin and nature.
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
203
Structure of Lipids03:38

Structure of Lipids

87.5K
Lipids include a diverse group of compounds that are largely nonpolar in nature. This is because they are hydrocarbons that include mostly nonpolar carbon-carbon or carbon-hydrogen bonds. Non-polar molecules are hydrophobic (“water fearing”), or insoluble in water. Lipids perform many different functions in a cell. Cells store energy for long-term use in the form of fats. Lipids also provide insulation from the environment for plants and animals. For example, they help keep aquatic...
87.5K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Precision Medicine for Electrocardiogram Interpretation: Clinical Relevance, Challenges, and Advances.

Reviews in cardiovascular medicine·2026
Same author

Impact of Timing of Atrial Fibrillation Ablation on AF Recurrence and Clinical Outcomes in Patients With HFpEF and HFrEF.

Journal of cardiovascular electrophysiology·2025
Same author

Palpitations After Leadless Pacemaker Implantation.

Circulation·2025
Same author

Global and Temporal Trends in Utilization and Outcomes of Implantable Cardioverter Defibrillators in Hypertrophic Cardiomyopathy.

Circulation. Arrhythmia and electrophysiology·2025
Same author

Impact of Diagnosis to Ablation Time on Recurrence of Atrial Fibrillation and Clinical Outcomes After Catheter Ablation: A Systematic Review and Meta-Analysis With Reconstructed Time-to-Event Data.

Circulation. Arrhythmia and electrophysiology·2025
Same author

Mitigation of pacing-induced cardiomyopathy with superficial right ventricular mid-septal pacing: A long-term retrospective comparison with apical pacing.

Journal of cardiovascular electrophysiology·2024
Same journal

A Bundle to Frame Guidelines and American Heart Association Statements.

Circulation·2026
Same journal

<i>Circulation</i> Editors and Editorial Board.

Circulation·2026
Same journal

A New <i>Circulation</i>, For You.

Circulation·2026
Same journal

Cardiovascular Risk Reduction With GLP-1 RA Drugs.

Circulation·2026
Same journal

Obesity, Severe Obesity, and Abdominal Obesity in US Youth and Adults From 1999 to 2023.

Circulation·2026
Same journal

Lipid Profile Testing and Interpretation.

Circulation·2026
関連記事をすべて見る

関連する実験動画

Updated: Jun 17, 2025

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

2.7K

オメガ 3 脂肪酸 と 心律 乱

Mason D Marcus1, Mark S Link1

  • 1Department of Medicine, Division of Cardiology, UT Southwestern Medical Center, Dallas, TX.

Circulation
|August 5, 2024
PubMed
まとめ
この要約は機械生成です。

オメガ3脂肪酸 (n-3 PUFA) は,心臓のリズムについて,異なった結果を示しています. いくつかの研究で利点が示唆されているが,高用量は心房細動 (AF) のリスクを増加させる可能性があるが,そのメカニズムはまだ不明である.

キーワード:
心房細動ドコサヘキサエノ酸エイコサペンタエノ酸オメガ3脂肪酸

さらに関連する動画

Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice
06:07

Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice

Published on: May 23, 2021

3.6K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.7K

関連する実験動画

Last Updated: Jun 17, 2025

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

2.7K
Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice
06:07

Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice

Published on: May 23, 2021

3.6K
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

17.7K

科学分野:

  • 心臓病科
  • 薬理学について
  • 生物化学

背景:

  • オメガ3 ポリ不飽和脂肪酸 (n-3 PUFA) は,鼓動障害の促進と抑制の両方について研究されています.
  • 初期の研究では,n-3 PUFAが突然の心臓死と心房細動 (AF) を予防することが示唆された.
  • しかし,最近の大規模なランダム化試験では,抗不律性効果に関して矛盾する結果が出ています.

研究 の 目的:

  • 心律不全,特に心筋梗塞に対する n-3 PUFA の複雑でしばしば矛盾する効果を評価する.
  • 心血管疾患の予防とAF管理におけるn-3 PUFA補給の有効性と安全性に関する現在の臨床的証拠を評価する.
  • 特定のn-3PUFA製剤と投与量の潜在的鼓動阻害効果を調査する.

主な方法:

  • ランダム化制御試験 (RCT) を含む臨床前試験とヒト臨床試験のレビュー
  • 心血管疾患の予防のために中等および高用量のn-3PUFA (エイコサペンタエノ酸 (EPA) とドコサヘキサエノ酸 (DHA) を含む) を調査した現代の大規模なRCTのデータ分析.
  • 対照群と比較してn-3 PUFAを受けた参加者におけるインシデントAFに関連する発見の検討.

主要な成果:

  • 手術後のAFまたは二次AFの予防のために n-3 PUFAの補給は支持されていません.
  • いくつかの大規模なRCTでは,プラセボと比較して,高用量のn-3PUFA (イコサペントエチルまたはEPA+DHA) を投与すると,小規模で,有意な,用量依存のAF増加が示されました.
  • これらのプロアリズム的発見は単療法と混合療法の両方で観察されましたが,根本的なメカニズムは不明です.

結論:

  • 心律不全,特にAFを予防するためのn-3PUFAの臨床的有用性は不確実であり,論争の的になる可能性があります.
  • イコサペントエチルなどの特定の製剤を含む高用量のn-3PUFAサプリメントは,AFの発症リスクを増加させる可能性があります.
  • EPA,DHA,およびその代謝産物の複雑な鼓動阻害および鼓動阻害メカニズムを明らかにし,より高いリスクのある患者のサブグループを特定するには,さらなる研究が必要です.